Xu Jack, Patel Keval V, Dsouza Melroy, Almendral Jesus, Mody Kanika, Iyer Deepa
Department of Internal Medicine, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ, USA.
Turk Kardiyol Dern Ars. 2018 Apr;46(3):231-233. doi: 10.5543/tkda.2017.74957.
Presently described is a case of disseminated adenovirus infection in a heart-kidney transplant recipient that was successfully treated with cidofovir. There are several reports of adenovirus infections in adult solid organ transplant recipients and the prognosis is usually poor, with mortality rates of 40% to 60%. Severe disseminated adenovirus infections have been associated with increased risk of adverse transplant events, such as rejection, ventricular dysfunction, allograft vasculopathy, graft loss, and the need for re-transplantation. The patient's lack of clinical improvement, the onset of hemorrhagic cystitis and acute kidney injury were factors in our decision to temporarily discontinue administration of immunosuppressive agents and start an antiviral agent. It is important to suspect adenovirus in transplant patients when they do not respond to antibiotics and cultures are negative. Early diagnosis and treatment are critical to improving outcomes in immunocompromised patients.
本文描述了一例心脏-肾脏移植受者发生播散性腺病毒感染,经西多福韦成功治疗的病例。有几篇关于成人实体器官移植受者腺病毒感染的报道,其预后通常较差,死亡率为40%至60%。严重的播散性腺病毒感染与移植不良事件风险增加有关,如排斥反应、心室功能障碍、移植血管病变、移植物丢失以及再次移植的必要性。患者缺乏临床改善、出血性膀胱炎和急性肾损伤的发生是我们决定暂时停用免疫抑制剂并开始使用抗病毒药物的因素。当移植患者对抗生素无反应且培养结果为阴性时,怀疑腺病毒感染很重要。早期诊断和治疗对于改善免疫功能低下患者的预后至关重要。